{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-093791","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2026-08-11T12:30:36+00:00","discovered_at":"2026-08-11T12:35:02.310845+00:00","generated_at":"2026-08-11T12:35:30.296371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adagio Medical posts Q2 2026 net loss of $6.7M; submits PMA for VT ablation system","bullets":["Net loss widened to $6.7M ($0.30/share) from $3.9M ($0.26) a year ago; revenue nil.","R&D spend $2.5M vs $2.0M; SG&A $2.5M vs $2.4M; cash $7.7M at June 30.","FULCRUM-VT trial (209 pts): 2.4% MAE, 84% freedom from ICD shock, 78% reduced/discontinued antiarrhythmics.","Submitted PMA to FDA for vCLAS Ventricular Ablation System for monomorphic VT in structural heart disease.","First patient treated with next-gen vCLAS Ultra catheter under FDA Expanded Access at Penn."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-093791","json":"https://secwatch.observer/filing/0001104659-26-093791.json","markdown":"https://secwatch.observer/filing/0001104659-26-093791.md","text":"https://secwatch.observer/filing/0001104659-26-093791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926093791/0001104659-26-093791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926093791/tm2622801d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:35:30.296371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}